Measuring retinal blood flow using advanced imaging techniques
Short- and Long-term Reproducibility of Dual Beam Doppler Fourier-domain Optical Coherence Tomography Measurements in Healthy Subjects - a Pilot Study
NA · Medical University of Vienna · NCT03821467
This study is testing a new imaging technique to see if it can reliably measure blood flow in the eyes of healthy people.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years to 35 Years |
| Sex | All |
| Sponsor | Medical University of Vienna (other) |
| Locations | 1 site (Vienna, State of Vienna) |
| Trial ID | NCT03821467 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the reproducibility of dual beam Doppler Fourier-domain Optical Coherence Tomography (DOCT) in measuring total retinal blood flow in healthy individuals. Participants will undergo blood flow measurements at various time points, including assessments during flickering light provocation to observe changes in vessel diameter and blood flow. The study will help establish the reliability of this noninvasive imaging technique for future applications in ocular health.
Who should consider this trial
Good fit: Ideal candidates for this study are healthy men and women aged 18 to 35 years who are non-smokers and have normal ophthalmic findings.
Not a fit: Patients with a history of significant illness, regular medication use, or those who are pregnant or lactating may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding and monitoring of ocular blood flow, potentially leading to better diagnostic tools for eye diseases.
How similar studies have performed: While the specific approach of dual beam Doppler DOCT may be novel, similar imaging techniques have shown promise in assessing ocular blood flow in previous studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Men and women aged between 18 and 35 years * Non-smokers * Normal findings in the medical history unless the investigator considers an abnormality to be clinically irrelevant * Normal ophthalmic findings, ametropy \< 3 Dpt. Exclusion Criteria: * Regular use of medication, abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study * Treatment in the previous 3 weeks with any drug (except contraceptives) * Symptoms of a clinically relevant illness in the 3 weeks before the first study day * Blood donation during the previous 3 weeks * Pregnancy, planned pregnancy or lactating * History or family history of epilepsia
Where this trial is running
Vienna, State of Vienna
- Medical University of Vienna, Department of Clinical Pharmacology — Vienna, State of Vienna, Austria (RECRUITING)
Study contacts
- Principal investigator: Doreen Schmidl, MD, PhD — Medical University of Vienna, Department of Clinical Pharmacology
- Study coordinator: Doreen Schmidl, MD, PhD
- Email: klin-pharmakologie@meduniwien.ac.at
- Phone: 0043140400
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Ocular Blood Flow, doppler optical coherence tomography, dynamic vessel analyzer